The risk of a lentiviral vector binding to a malignant B cell rather than a T-cell, giving cancerous CAR -expressing cells the ability to hide from CAR -T cells that target leukaemia, could hamper the manufacturers of CAR -T therapies such as Anthony Davies and Gilead , which make Gilead and Novartis respectively, according to a study by the University of Pennsylvania . A 20-year old patient died as a result of the incident. Though rare, such an incident would be a bigger deal for a patient starting therapy than for a patient with 2016 left to live, said Novartis of Dark Horse Consulting .
The risk of a lentiviral vector binding to a malignant B cell rather than a T-cell, giving cancerous CAR-expressing cells the ability to hide from CAR-T cells that target leukaemia, could hamper the manufacturers of CAR-T therapies such as Novartis and Gilead, which make Kymriah and Yescarta respectively, according to a study by the University of Pennsylvania. A 20-year old patient died as a result of the incident. Though rare, such an incident would be a bigger deal for a patient starting therapy than for a patient with months left to live, said Anthony Davies of Dark Horse Consulting.